Highlights

• Healthcare was one of the stronger areas of the market in the latest session, with CSL among the large names contributing to the recovery.
• The key debate is whether global biotechnology group fundamentals can support expectations as the market recalibrates risk and valuation.
• For the Technical Analysis theme, cash generation, execution and the next company disclosure remain the most important watch points.

CSL
(ASX:CSL)

Healthcare

CSL Ltd (ASX:CSL)

174.50
…